Jazz Pharmaceuticals is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $116.82 – a decrease of 6% over the previous week. Jazz Pharmaceuticals employs 2,800 staff and has a trailing 12-month revenue of around $4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $116.82 |
|---|---|
| 52-week range | $99.06 - $134.17 |
| 50-day moving average | $111.93 |
| 200-day moving average | $112.96 |
| Wall St. target price | $179.83 |
| PE ratio | 18.0888 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $6.87 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $117.59 from 2024-11-18
| 1 week (2024-11-13) | -7.88% |
|---|---|
| 1 month (2024-10-18) | 2.22% |
| 3 months (2024-08-20) | 2.28% |
| 6 months (2024-05-20) | 8.26% |
| 1 year (2023-11-20) | -2.54% |
|---|---|
| 2 years (2022-11-18) | -20.10% |
| 3 years (2021-11-19) | 128.37 |
| 5 years (2019-11-20) | 140.65 |
Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jazz Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Jazz Pharmaceuticals shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.991. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 billion.
The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 24.67% |
| Gross profit TTM | $3.4 billion |
| Return on assets TTM | 4.62% |
| Return on equity TTM | 12.09% |
| Profit margin | 11.6% |
| Book value | $69.01 |
| Market Capitalization | $7.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 31.66
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 12/31/2018) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.18/100
Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.74/100
Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.74/100
Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.
Jazz Pharmaceuticals PLC was last rated for ESG on: 2019-01-01.
| Total ESG score | 31.66 |
|---|---|
| Total ESG percentile | 51.04 |
| Environmental score | 4.18 |
| Environmental score percentile | 8 |
| Social score | 24.74 |
| Social score percentile | 8 |
| Governance score | 13.74 |
| Governance score percentile | 8 |
| Level of controversy | 1 |
We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $99.06 up to $134.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.573. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.